First Time Loading...

Gain Therapeutics Inc
NASDAQ:GANX

Watchlist Manager
Gain Therapeutics Inc Logo
Gain Therapeutics Inc
NASDAQ:GANX
Watchlist
Price: 3.03 USD -1.3% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

GANX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. [ Read More ]

The intrinsic value of one GANX stock under the Base Case scenario is 0.07 USD. Compared to the current market price of 3.03 USD, Gain Therapeutics Inc is Overvalued by 98%.

Key Points:
GANX Intrinsic Value
Base Case
0.07 USD
Overvaluation 98%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Gain Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GANX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Gain Therapeutics Inc

Provide an overview of the primary business activities
of Gain Therapeutics Inc.

What unique competitive advantages
does Gain Therapeutics Inc hold over its rivals?

What risks and challenges
does Gain Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Gain Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gain Therapeutics Inc.

Provide P/S
for Gain Therapeutics Inc.

Provide P/E
for Gain Therapeutics Inc.

Provide P/OCF
for Gain Therapeutics Inc.

Provide P/FCFE
for Gain Therapeutics Inc.

Provide P/B
for Gain Therapeutics Inc.

Provide EV/S
for Gain Therapeutics Inc.

Provide EV/GP
for Gain Therapeutics Inc.

Provide EV/EBITDA
for Gain Therapeutics Inc.

Provide EV/EBIT
for Gain Therapeutics Inc.

Provide EV/OCF
for Gain Therapeutics Inc.

Provide EV/FCFF
for Gain Therapeutics Inc.

Provide EV/IC
for Gain Therapeutics Inc.

Show me price targets
for Gain Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Gain Therapeutics Inc?

How accurate were the past Revenue estimates
for Gain Therapeutics Inc?

What are the Net Income projections
for Gain Therapeutics Inc?

How accurate were the past Net Income estimates
for Gain Therapeutics Inc?

What are the EPS projections
for Gain Therapeutics Inc?

How accurate were the past EPS estimates
for Gain Therapeutics Inc?

What are the EBIT projections
for Gain Therapeutics Inc?

How accurate were the past EBIT estimates
for Gain Therapeutics Inc?

Compare the revenue forecasts
for Gain Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gain Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gain Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gain Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Gain Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Gain Therapeutics Inc with its peers.

Analyze the financial leverage
of Gain Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Gain Therapeutics Inc.

Provide ROE
for Gain Therapeutics Inc.

Provide ROA
for Gain Therapeutics Inc.

Provide ROIC
for Gain Therapeutics Inc.

Provide ROCE
for Gain Therapeutics Inc.

Provide Gross Margin
for Gain Therapeutics Inc.

Provide Operating Margin
for Gain Therapeutics Inc.

Provide Net Margin
for Gain Therapeutics Inc.

Provide FCF Margin
for Gain Therapeutics Inc.

Show all solvency ratios
for Gain Therapeutics Inc.

Provide D/E Ratio
for Gain Therapeutics Inc.

Provide D/A Ratio
for Gain Therapeutics Inc.

Provide Interest Coverage Ratio
for Gain Therapeutics Inc.

Provide Altman Z-Score Ratio
for Gain Therapeutics Inc.

Provide Quick Ratio
for Gain Therapeutics Inc.

Provide Current Ratio
for Gain Therapeutics Inc.

Provide Cash Ratio
for Gain Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Gain Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Gain Therapeutics Inc?

What is the current Free Cash Flow
of Gain Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gain Therapeutics Inc.

Financials

Balance Sheet Decomposition
Gain Therapeutics Inc

Current Assets 17.8m
Cash & Short-Term Investments 16.8m
Receivables 242.6k
Other Current Assets 741.6k
Non-Current Assets 830.5k
PP&E 778.6k
Other Non-Current Assets 51.9k
Current Liabilities 4.9m
Accounts Payable 1.3m
Accrued Liabilities 2m
Other Current Liabilities 1.7m
Non-Current Liabilities 1.1m
Long-Term Debt 449.1k
Other Non-Current Liabilities 632.1k
Efficiency

Earnings Waterfall
Gain Therapeutics Inc

Revenue
55.2k USD
Operating Expenses
-22.3m USD
Operating Income
-22.3m USD
Other Expenses
-14.4k USD
Net Income
-22.3m USD

Free Cash Flow Analysis
Gain Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

GANX Profitability Score
Profitability Due Diligence

Gain Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
19/100
Profitability
Score

Gain Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

GANX Solvency Score
Solvency Due Diligence

Gain Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
64/100
Solvency
Score

Gain Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GANX Price Targets Summary
Gain Therapeutics Inc

Wall Street analysts forecast GANX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GANX is 8.98 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
100% Upside
Average
Price Target
8.98 USD
196% Upside
Highest
Price Target
10.5 USD
247% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GANX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GANX Price
Gain Therapeutics Inc

1M 1M
-19%
6M 6M
+5%
1Y 1Y
-39%
3Y 3Y
-75%
5Y 5Y
-73%
10Y 10Y
-73%
Annual Price Range
3.03
52w Low
2.07
52w High
5.5
Price Metrics
Average Annual Return -45.94%
Standard Deviation of Annual Returns 7.77%
Max Drawdown -87%
Shares Statistics
Market Capitalization 49.8m USD
Shares Outstanding 16 219 700
Percentage of Shares Shorted 0.91%

GANX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Gain Therapeutics Inc Logo
Gain Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

49.8m USD

Dividend Yield

0%

Description

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2021-03-18. The Company, through its subsidiary, GT Gain Therapeutics SA, is a development stage biotechnology company. The firm is focused on developing therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. The company uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which are small molecules with the potential to treat diseases with unmet medical need. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.

Contact

MARYLAND
Bethesda
4800 Hampden Lane, Suite 200
+13015001556.0
https://www.gaintherapeutics.com/

IPO

2021-03-18

Employees

25

Officers

Founder & Chairman
Dr. Khalid Islam Ph.D.
President, CEO & Director
Mr. Matthias Alder LIC. IUR., LL.M.
VP of Finance, Senior Dir. of Corp. Reporting, Principal Acc. Off., & Principal Financial Off.
Mr. Gianluca Fuggetta
GM & Chief Strategy Officer
Dr. Manolo Bellotto Ph.D.
Senior Vice President of Research
Dr. Joanne Taylor Ph.D.
Senior Vice President of Technical Operations
Dr. Terenzio Ignoni Pharm.D.

See Also

Discover More
What is the Intrinsic Value of one GANX stock?

The intrinsic value of one GANX stock under the Base Case scenario is 0.07 USD.

Is GANX stock undervalued or overvalued?

Compared to the current market price of 3.03 USD, Gain Therapeutics Inc is Overvalued by 98%.